TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06086730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blow bottle positive expiratory pressure
Description: Water was poured into a 1 L plastic container until it reached a 10 cm height. A 30 cm long tube was put into the water in the bottle, 8 cm deep. The participants were instructed to close their mouths around the tubing in the apparatus for three seconds to produce bubbles, do this for a total of 10 breaths, perform two huffs, then cough. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized,Because it is a homemade device and can be used with less equipment and with more ease at home . patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acapella
Description: Make sure the frequency adjustment dial has been rotated counterclockwise to the lowest frequency-resistance setting before using the Acapella for the first time.On a chair, adopt a straight stance. maintaining a straight back and relaxing your elbows on a table. Now gradually tilt your head upward to maintain the opening of your upper airways.Inhale more deeply than you frequently do. Make sure your lips are encircling the mouthpiece, then blow into the device with a strong expiration.You should ideally blow out roughly twice as quickly as usual.For around ten breaths, keep going like this.Make careful to expel to clear the secretions from the airways after the final try. You can even conduct 2 to 3 huffs to improve secretion elimination when necessary.It should be noted that while using the device, you must be capable of exhale for a minimum of three to four seconds. patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes
Study: NCT04230408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation
Study: NCT06019312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sanprobi IBS®
Description: Patients will be treated with probiotics in combination with inulin, which is able to stimulate the growing of probiotic bacteria in gastrointestinal tract.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sanprobi IBS®
Description: Patients will be treated with probiotics in combination with inulin, which is able to stimulate the growing of probiotic bacteria in gastrointestinal tract.
Study: NCT05625048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transperinal ultrasound guided instruction in pelvic floor muscle training
Description: The physiotherapists uses transperinal ultrasound as a biofeedback or pedagogical tool to improve the muscle contractions and visualize the muscle work.
Study: NCT05250596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
Study: NCT03941587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
Description: Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)
Description: Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy
Study: NCT06358040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opioid-Dispensing Device
Description: Addinex Opioid-Dispensing Device
Study: NCT05470478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile neural decoding platform (mobile iBCI)
Description: An embedded neural signal processor device will be evaluated for its ability to provide accurate and reliable closed-loop control in a home-based brain-computer interface.
Study: NCT06373757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nano-HAP/Chitosan hydrogel
Description: The periodontal pockets more than or equal 3-5mm were isolated. Chitosan and nano-HAP hydrogel were prepared in the same steps that were mentioned in the methodology and then the prepared gel was applied to the test site of patients with the deepest probing pocket measurement once per week for 3 weeks. Periodontal dressing (Coe-pack) was to secure the hydrogel in place.
Study: NCT06053567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).
Study: NCT06276855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep hygiene education
Description: The sleep hygiene education booklet was prepared by the researchers by in line with the literature. The booklet contains information on the definition and benefits of sleep, sleep problems during insomnia, arrangements for regular sleep, and the principles of sleep hygiene. The principles of sleep hygiene include individual habits that facilitate sleep, proper arrangement of the physical environment, exercises before going to bed, and dietary habits. This educational content was applied to those in the experimental group. The education took an average of 30 minutes.
Study: NCT06358040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App
Description: Addinex App

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: App
Description: Addinex App

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Opioid Pill Bottle
Description: Standard Opioid Pill Bottle
Study: NCT05771753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercises
Description: 6 stretching exercises 2 repetitions x1 set, 3 days/week and targeted muscles stretching (Lower Back, Lower limb)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic core stabilizing exercises
Description: This group received core stabilizing exercises 2 repetitions x1 set, 3 days/week and the targeted muscles were abdominals, lower back, and lower limb.
Study: NCT06139874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: Early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: Early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Wisely
Description: Online asynchronous parenting program.
Study: NCT06635044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intradialytic exercise
Description: HD men came to the HD unit three times weekly to receive their dialysis session which consumed 3-4 hours. During the first two hours of the men's dialysis session, a pedal exerciser (RTL10273 Deluxe Folding Pedal Exerciser, Drive Medical Co. MPN) was utilized in performing leg cycling exercises while men were sitting. Before starting the session of intradialytic cycling, a 5-minute stretching of the lower limbs was performed as a warming up. Also, as cooling down, the same period of lower limbs' stretching was performed after ending intradialytic cycling
Study: NCT06635967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frequency-specific rTMS
Description: Patterned repetitive transcranial magnetic stimulation will be performed at specific frequencies and inter-train intervals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1 Hz rTMS
Description: Low-frequency rTMS will be performed at a frequency of 1Hz
Study: NCT06636188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digi-Coach Chatbot
Description: Participants will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer related concerns in the chatbot.
Study: NCT06635707

Intervention type: DRUG
Intervention: Urapidil
Description: 1. Control systolic blood pressure within 130-140mmHg using urapidil and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, positioning of the body, and other means to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the use of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants.

Intervention type: DRUG
Intervention: Urapidil and Esmolol
Description: 1. Utilize both urapidil and esmolol to control systolic blood pressure within 130-140mmHg and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, strategic positioning of the body, and other measures to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the administration of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants.
Study: NCT06364657

Intervention type: DIAGNOSTIC_TEST
Intervention: Eye Exam
Description: * Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS)~* Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey~* Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test.~* Corneal esthesiometer for measurement of corneal sensation~* Schirmer's without topical anesthesia~* Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT)~* Staining for dry eye:~* Tear film break-up time (BUT) using fluorescein.~* Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS))~* Lissamine green staining (OSS and Oxford)~* Non-contact confocal biomicroscopy for morphology of the ocular surface

Intervention type: DIAGNOSTIC_TEST
Intervention: Eye Exam
Description: * Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS)~* Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey~* Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test.~* Corneal esthesiometer for measurement of corneal sensation~* Schirmer's without topical anesthesia~* Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT)~* Staining for dry eye:~* Tear film break-up time (BUT) using fluorescein.~* Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS))~* Lissamine green staining (OSS and Oxford)~* Non-contact confocal biomicroscopy for morphology of the ocular surface
Study: NCT05556772

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Collection of blood; urine; cervical, anal, vaginal samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Attend interview
Study: NCT06285383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Participants will listen to the music pieces Pachabel Canon in D major (30 minutes), free from external sounds (max 70 dB through headphones).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classic physical therapy
Description: classic physical therapy

Intervention type: OTHER
Group type: OTHER
Intervention: classic physical therapy
Description: classic physical therapy
Study: NCT05766124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator
Description: Intrapleural administration of tissue plasminogen activator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: Intrapleural administration of tissue plasminogen activator
Study: NCT06715163

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1 (42mg) of DAO
Description: DAO extract is obtained from pea sprout dehydrated powder. Lowest dose of DAO administered in this study
Study: NCT06529224

Intervention type: OTHER
Intervention: Online questionnaire
Description: An online questionnaire will be distributed in electronic format to all the healthcare professionals concerned.
Study: NCT06364657

Intervention type: DIAGNOSTIC_TEST
Intervention: Eye Exam
Description: * Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS)~* Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey~* Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test.~* Corneal esthesiometer for measurement of corneal sensation~* Schirmer's without topical anesthesia~* Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT)~* Staining for dry eye:~* Tear film break-up time (BUT) using fluorescein.~* Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS))~* Lissamine green staining (OSS and Oxford)~* Non-contact confocal biomicroscopy for morphology of the ocular surface
Study: NCT05608187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2
Description: Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 5x10\^7 CFU/cm\^2 wound area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2
Description: Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 1x10\^9 CFU/cm\^2 wound area.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application of placebo (ILP100 dilution buffer mixed with the activation peptide SppIP).
Study: NCT05443620

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Weight vest
Description: A vest weighing up to a maximum of 15 kg.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wheelchair
Description: Wheelchair in which participants will be sitting to reduce loading on lower extremities.
Study: NCT04441047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: Living, activated allogeneic Th1-like memory immune cells
Study: NCT05990062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-Socket-Harness
Description: A transradial socket and harness design that offers a hybrid polymer and textile-based design derived from advanced athletic shoe technology. The KSH integrated socket, frame, and wrist, the variable compliance prosthetic socket with breathable matrix, creates a dynamic and secure attachment with a combination of two lacing systems. The lacing systems lengthen and shorten six flexible hinges at the elbow, maintaining a secure attachment throughout the range of motion and accounting for volume changes in the soft tissue of the elbow that would otherwise restrict range of motion or cause the socket to separate from the residual limb.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-Socket-Harness
Description: A transradial socket and harness design that offers a hybrid polymer and textile-based design derived from advanced athletic shoe technology. The KSH integrated socket, frame, and wrist, the variable compliance prosthetic socket with breathable matrix, creates a dynamic and secure attachment with a combination of two lacing systems. The lacing systems lengthen and shorten six flexible hinges at the elbow, maintaining a secure attachment throughout the range of motion and accounting for volume changes in the soft tissue of the elbow that would otherwise restrict range of motion or cause the socket to separate from the residual limb.
Study: NCT06487858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-R046
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-R046
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-R046
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous administration
Study: NCT06715163

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains the same excipients as the DAO tablets but without the diamino oxidase content

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 2 (84mg) of DAO
Description: DAO extract is obtained from pea sprout dehydrated powder. Medium dose of DAO administered in this study
Study: NCT06487858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous administration
Study: NCT06715163

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 3 (210mg) of DAO
Description: DAO extract is obtained from pea sprout dehydrated powder. Highest dose of DAO administered in this study
Study: NCT06721585

Intervention type: DRUG
Intervention: Tecovirimat Oral Capsule [Tpoxx]
Description: Tecovirimat Oral Capsule 200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)

Intervention type: OTHER
Intervention: Standard of Care (SOC)
Description: Participants are provided SOC for mpox
Study: NCT06450210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin trihydrate
Description: Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin trihydrate
Description: Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin trihydrate
Description: Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin trihydrate
Description: Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.
Study: NCT05181449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twin Precision Treatment
Description: Combination of Artificial Intelligence algorithms based on daily sensor input and live nutrition, exercise, sleep and breath coaching to help treat type 2 diabetes
Study: NCT06396247

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Activity Strength Training
Description: FAST consists of five exercises (stepping on a step, chair stands, push-ups, rows, walking), for 30 seconds each, performed daily, with 30 seconds of rest between.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Activity Strength Training
Description: FAST consists of five exercises (stepping on a step, chair stands, push-ups, rows, walking), for 30 seconds each, performed daily, with 30 seconds of rest between.